advertisement
Molecular Therapy 32
Showing records 1 to 25 | Display all abstracts in Molecular Therapy98223 Endosomal disentanglement of a transducible artificial transcription factor targeting endothelin receptor A
Bippes CC
Molecular Therapy 2022; 30: 855-867
98727 NMNAT2 is downregulated in glaucomatous RGCs, and RGC-specific gene therapy rescues neurodegeneration and visual function
Fang F
Molecular Therapy 2022; 30: 1421-1431
98807 CRISPR genome surgery in a novel humanized model for autosomal dominant retinitis pigmentosa
Wu WH; Tsai YT
Molecular Therapy 2022; 30: 1407-1420
98727 NMNAT2 is downregulated in glaucomatous RGCs, and RGC-specific gene therapy rescues neurodegeneration and visual function
Zhuang P
Molecular Therapy 2022; 30: 1421-1431
98223 Endosomal disentanglement of a transducible artificial transcription factor targeting endothelin receptor A
Kohler C; Garcia-Tirado E
Molecular Therapy 2022; 30: 855-867
98807 CRISPR genome surgery in a novel humanized model for autosomal dominant retinitis pigmentosa
Huang IW
Molecular Therapy 2022; 30: 1407-1420
98727 NMNAT2 is downregulated in glaucomatous RGCs, and RGC-specific gene therapy rescues neurodegeneration and visual function
Feng X
Molecular Therapy 2022; 30: 1421-1431
98807 CRISPR genome surgery in a novel humanized model for autosomal dominant retinitis pigmentosa
Huang IW; Cheng CH
Molecular Therapy 2022; 30: 1407-1420
98727 NMNAT2 is downregulated in glaucomatous RGCs, and RGC-specific gene therapy rescues neurodegeneration and visual function
Liu P
Molecular Therapy 2022; 30: 1421-1431
98223 Endosomal disentanglement of a transducible artificial transcription factor targeting endothelin receptor A
Burri R
Molecular Therapy 2022; 30: 855-867
98727 NMNAT2 is downregulated in glaucomatous RGCs, and RGC-specific gene therapy rescues neurodegeneration and visual function
Liu D
Molecular Therapy 2022; 30: 1421-1431
98807 CRISPR genome surgery in a novel humanized model for autosomal dominant retinitis pigmentosa
Hsu CW
Molecular Therapy 2022; 30: 1407-1420
98223 Endosomal disentanglement of a transducible artificial transcription factor targeting endothelin receptor A
Frauenknecht T; Gerard MA
Molecular Therapy 2022; 30: 855-867
98807 CRISPR genome surgery in a novel humanized model for autosomal dominant retinitis pigmentosa
Cui X
Molecular Therapy 2022; 30: 1407-1420
98727 NMNAT2 is downregulated in glaucomatous RGCs, and RGC-specific gene therapy rescues neurodegeneration and visual function
Huang H; Li L
Molecular Therapy 2022; 30: 1421-1431
98223 Endosomal disentanglement of a transducible artificial transcription factor targeting endothelin receptor A
Salat M
Molecular Therapy 2022; 30: 855-867
98807 CRISPR genome surgery in a novel humanized model for autosomal dominant retinitis pigmentosa
Ryu J; Quinn PMJ
Molecular Therapy 2022; 30: 1407-1420
98727 NMNAT2 is downregulated in glaucomatous RGCs, and RGC-specific gene therapy rescues neurodegeneration and visual function
Chen W
Molecular Therapy 2022; 30: 1421-1431
98807 CRISPR genome surgery in a novel humanized model for autosomal dominant retinitis pigmentosa
Quinn PMJ
Molecular Therapy 2022; 30: 1407-1420
98223 Endosomal disentanglement of a transducible artificial transcription factor targeting endothelin receptor A
Allenspach R
Molecular Therapy 2022; 30: 855-867
98807 CRISPR genome surgery in a novel humanized model for autosomal dominant retinitis pigmentosa
Quinn PMJ
Molecular Therapy 2022; 30: 1407-1420
98727 NMNAT2 is downregulated in glaucomatous RGCs, and RGC-specific gene therapy rescues neurodegeneration and visual function
Liu L
Molecular Therapy 2022; 30: 1421-1431
98807 CRISPR genome surgery in a novel humanized model for autosomal dominant retinitis pigmentosa
Caruso SM; Caruso SM
Molecular Therapy 2022; 30: 1407-1420
98223 Endosomal disentanglement of a transducible artificial transcription factor targeting endothelin receptor A
Agca C; Wu Z
Molecular Therapy 2022; 30: 855-867
98727 NMNAT2 is downregulated in glaucomatous RGCs, and RGC-specific gene therapy rescues neurodegeneration and visual function
Sun Y
Molecular Therapy 2022; 30: 1421-1431
